Preferred Label : immunoglobulin fc fragments;

MeSH definition : Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.;

MeSH synonym : immunoglobulins, fc fragment; fc fragment, immunoglobulin; fc immunoglobulins; fc fragments; immunoglobulins, fc; fragment immunoglobulins, fc; immunoglobulin fc fragment; fc fragments, immunoglobulin; fc fragment immunoglobulins; Ig Fc Fragments; Fc Fragments, Ig; Fragments, Ig Fc; Fc Fragment; Fragment, Fc; Fc Immunoglobulin; Immunoglobulin, Fc;

MeSH annotation : DF: IG FC;

Is substance : O;

Details


Main resources

You can consult :

Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.

https://www.has-sante.fr/jcms/p_3281010/fr/reblozyl-25-ss-thalassemie-luspatercept
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
adult
anemia
beta-Thalassemia
blood transfusion
Transfusion dependent anaemia
Product containing precisely luspatercept 25 milligram/1 vial powder for conventional release solution for injection (clinical drug)
Product containing precisely luspatercept 75 milligram/1 vial powder for conventional release solution for injection (clinical drug)
injections, subcutaneous
hematinics
luspatercept
evaluation of the transparency committee
luspatercept
Reblozyl
immunoglobulin fc fragments
recombinant fusion proteins
activin receptors, type ii

---
https://www.has-sante.fr/jcms/p_3225392/fr/trulicity
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
diabetes mellitus, type 2
injections, subcutaneous
hypoglycemic agents
adult
drug therapy, combination
Product containing only dulaglutide (medicinal product)
evaluation of the transparency committee
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins

---
https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
luspatercept
luspatercept
luspatercept
hematinics
hematinics
orphan drug production
anemia
myelodysplastic syndromes
beta-Thalassemia
injections, subcutaneous
product surveillance, postmarketing
Transfusion dependent anemia
adult
pregnancy
breast feeding
drug evaluation, preclinical
Product containing precisely luspatercept 25 milligram/1 vial powder for conventional release solution for injection (clinical drug)
Product containing precisely luspatercept 75 milligram/1 vial powder for conventional release solution for injection (clinical drug)
immunoglobulin fc fragments
recombinant fusion proteins
activins
immunoglobulin fc fragments
recombinant fusion proteins
activins

---
https://www.usherbrooke.ca/baladocritique/archives/episode-26-etude-rewind/
2019
false
false
false
false
Canada
immunoglobulin fc fragments
glucagon-like peptides
recombinant fusion proteins
cardiovascular diseases
treatment outcome
hypoglycemic agents
Glucagon-Like Peptide-1 Receptor
sound
diabetes mellitus, type 2
dulaglutide

---
http://www.has-sante.fr/portail/jcms/c_2682507/fr/alprolix-eftrenonacog-alpha
2017
false
false
false
France
French
guidelines for drug use
evaluation of the transparency committee
treatment outcome
factor IX
factor IX
coagulation factor IX
hemophilia B
recombinant fusion proteins
hemorrhage
hemorrhage
orphan drug production
recombinant fusion proteins
adult
adolescent
child
continuity of patient care
injections, intravenous
Eftrenonacog alfa (substance)
factor IX Fc fusion protein
factor IX Fc fusion protein
immunoglobulin fc fragments
immunoglobulin fc fragments

---
Summary Basis of Decision (SBD) for Trulicity
Dulaglutide, 0.75 mg/0.5 mL and 1.5 mg/0.5 mL, solution, subcutaneous injection
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00244
2016
false
false
false
Canada
French
English
treatment outcome
summary of product characteristics
immunoglobulin fc fragments
recombinant fusion proteins
drug approval
hypoglycemic agents
hypoglycemic agents
glucagon-like peptides
adult
diabetes mellitus, type 2
drug therapy, combination
injections, subcutaneous
aged
Glycated Hemoglobin
drug evaluation, preclinical
canada
metformin
sulfonylurea compounds
insulin
Glucagon-Like Peptide-1 Receptor
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
dulaglutide
dulaglutide

---
http://www.has-sante.fr/portail/jcms/c_2617853/fr/elocta
http://www.has-sante.fr/portail/jcms/c_2617853/fr/elocta-efmoroctocog-alfa-facteur-viii
2016
false
false
false
France
French
treatment outcome
factor VIII-Fc fusion protein
factor VIII-Fc fusion protein
coagulation factor VIII
hemophilia A
hemorrhage
hemorrhage
orphan drug production
injections, intravenous
evaluation of the transparency committee
adult
adolescent
child
guidelines for drug use
factor VIII
immunoglobulin fc fragments
recombinant fusion proteins
factor VIII
immunoglobulin fc fragments
recombinant fusion proteins

---
http://www.riziv.fgov.be/SiteCollectionDocuments/consensus_litterature_resume_20161117.pdf
2016
false
false
false
Belgium
French
GLP-1 Mimetics
diabetes mellitus, type 2
review of literature
consensus
GLP-1 Mimetics
treatment outcome
albiglutide
albiglutide
Glucagon-like peptide-1 (GLP-1) analogues
drug therapy, combination
metformin
hypoglycemic agents
hypoglycemic agents
glimepiride
dulaglutide
dulaglutide
Liraglutide
Liraglutide
Sitagliptin Phosphate
sulfonylurea compounds
comparative effectiveness research
arterial pressure
insulin
thyroid neoplasms
pancreatitis
Injection Site Reaction
cardiovascular diseases
practice guidelines as topic
Evidence-Based medicine
rGLP-1 protein
rGLP-1 protein
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
peptides
venoms
peptides
venoms
thiazolidinediones
Pioglitazone
Exenatide
Exenatide

---
https://www.ema.europa.eu/medicines/human/EPAR/Alprolix
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
treatment outcome
product surveillance, postmarketing
coagulation factor IX
orphan drug production
hemophilia B
hemorrhage
hemorrhage
injections, intravenous
factor IX Fc fusion protein
factor IX Fc fusion protein
pregnancy
breast feeding
adult
child
drug evaluation, preclinical
Eftrenonacog alfa (substance)
factor IX
immunoglobulin fc fragments
recombinant fusion proteins
factor IX
immunoglobulin fc fragments
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_2036398/fr/trulicity
http://www.has-sante.fr/portail/jcms/c_2036398/fr/trulicity-dulaglutide-antidiabetique
2015
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
drug therapy, combination
insulins
dulaglutide
dulaglutide
hypoglycemic agents
hypoglycemic agents
glucagon-like peptide 1
diabetes mellitus, type 2
metformin
adult
injections, subcutaneous
dulaglutide
dulaglutide
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides

---
https://www.ema.europa.eu/medicines/human/EPAR/Trulicity
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
immunoglobulin fc fragments
recombinant fusion proteins
drug approval
europe
hypoglycemic agents
hypoglycemic agents
glucagon-like peptides
adult
diabetes mellitus, type 2
drug therapy, combination
injections, subcutaneous
Pre-filled Pen Syringe
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
Glycated Hemoglobin
drug evaluation, preclinical
Prefilled Syringe Dosage Form
Glucagon-Like Peptide-1 Receptor
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
dulaglutide
dulaglutide

---
https://www.ema.europa.eu/medicines/human/EPAR/Elocta
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
factor VIII-Fc fusion protein
factor VIII-Fc fusion protein
hemophilia A
hemorrhage
hemorrhage
orphan drug production
product surveillance, postmarketing
injections, intravenous
pregnancy
breast feeding
drug evaluation, preclinical
coagulation factor VIII
factor VIII
immunoglobulin fc fragments
recombinant fusion proteins
factor VIII
immunoglobulin fc fragments
recombinant fusion proteins

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00172
2014
false
false
false
Canada
French
English
factor IX
factor IX
drug approval
canada
recombinant fusion proteins
recombinant fusion proteins
risk assessment
drug evaluation
adult
child
hemophilia B
hemorrhage
clinical trials as topic
treatment outcome
intraoperative care
summary of product characteristics
factor IX Fc fusion protein
factor IX Fc fusion protein
immunoglobulin fc fragments
immunoglobulin fc fragments

---
Summary Basis of Decision (SBD) for Eloctate
Antihemophilic Factor (Recombinant BDD), Fc Fusion Protein, 250, 500, 750, 1,000, 1,500, 2,000, 3,000 IU/vial, powder for solution, intravenous
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00210
2014
false
false
false
Canada
French
English
drug information
adult
child
hemophilia A
hemorrhage
factor VIII
factor VIII
coagulation factor VIII
coagulants
coagulants
immunoglobulin fc fragments
immunoglobulin fc fragments
recombinant fusion proteins
recombinant fusion proteins
drug approval
canada
treatment outcome
chemoprevention
hemorrhage

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.